Literature DB >> 19585352

Hyperlexia and ambient echolalia in a case of cerebral infarction of the left anterior cingulate cortex and corpus callosum.

Tadashi Suzuki1, Shouichi Itoh, Mototaka Hayashi, Masako Kouno, Katsuhiko Takeda.   

Abstract

We report the case of a 69-year-old woman with cerebral infarction in the left anterior cingulate cortex and corpus callosum. She showed hyperlexia, which was a distinctive reading phenomenon, as well as ambient echolalia. Clinical features also included complex disorders such as visual groping, compulsive manipulation of tools, and callosal disconnection syndrome. She read words written on the cover of a book and repeated words emanating from unrelated conversations around her or from hospital announcements. The combination of these two features due to a focal lesion has never been reported previously. The supplementary motor area may control the execution of established subroutines according to external and internal inputs. Hyperlexia as well as the compulsive manipulation of tools could be interpreted as faulty inhibition of preexisting essentially intact motor subroutines by damage to the anterior cingulate cortex reciprocally interconnected with the supplementary motor area.

Entities:  

Mesh:

Year:  2009        PMID: 19585352     DOI: 10.1080/13554790902842037

Source DB:  PubMed          Journal:  Neurocase        ISSN: 1355-4794            Impact factor:   0.881


  3 in total

1.  Sign Language Echolalia in Deaf Children With Autism Spectrum Disorder.

Authors:  Aaron Shield; Frances Cooley; Richard P Meier
Journal:  J Speech Lang Hear Res       Date:  2017-06-10       Impact factor: 2.297

2.  Echolalia Following Acute Ischemic Stroke.

Authors:  Ali H Abusrair; Fatimah AlSaeed
Journal:  Neurohospitalist       Date:  2020-09-10

3.  Thinking on Treating Echolalia in Aphasia: Recommendations and Caveats for Future Research Directions.

Authors:  Marcelo L Berthier; María J Torres-Prioris; Diana López-Barroso
Journal:  Front Hum Neurosci       Date:  2017-04-03       Impact factor: 3.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.